Michael Preston Heinbach, AGACNP-BC, ACCNS-AG | |
505 Parnassus Ave # 7long, San Francisco, CA 94143-2204 | |
(415) 353-1387 | |
Not Available |
Full Name | Michael Preston Heinbach |
---|---|
Gender | Male |
Speciality | Nurse Practitioner - Gerontology |
Location | 505 Parnassus Ave # 7long, San Francisco, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013654995 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | 95017584 (California) | Secondary |
363LG0600X | Nurse Practitioner - Gerontology | 95017584 (California) | Primary |
Entity Name | University Of California San Francisco |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.
Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Naratriptan Tablets USP, 1mg and 2.5mg by the U.S. Food and Drug Administration. The product is available in bottles of 9 for immediate shipment to wholesalers and pharmacies nationwide.
With increasing concern about concussions from sports, some players have started wearing electronic sensors to measure head impacts.
Parents and teachers concerned about a child's mental health and development can now get immediate answers from an online screening with Project SKIP.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Michael Preston Heinbach, AGACNP-BC, ACCNS-AG 505 Parnassus Ave # 7long, San Francisco, CA 94143-2204 Ph: (415) 353-1387 | Michael Preston Heinbach, AGACNP-BC, ACCNS-AG 505 Parnassus Ave # 7long, San Francisco, CA 94143-2204 Ph: (415) 353-1387 |
News Archive
Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.
Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Naratriptan Tablets USP, 1mg and 2.5mg by the U.S. Food and Drug Administration. The product is available in bottles of 9 for immediate shipment to wholesalers and pharmacies nationwide.
With increasing concern about concussions from sports, some players have started wearing electronic sensors to measure head impacts.
Parents and teachers concerned about a child's mental health and development can now get immediate answers from an online screening with Project SKIP.
› Verified 3 days ago